Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III)

		Phase:		Phase 2/3

		Treatment ID#:		1765 CDX110-003

		Age Group:		Adults Only

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed

		Last Updated:		03/09/2010

		Tumor Types:		Glioblastoma Multiforme


		Comments:		This trial is for newly diagnosed patients, after having completed surgery, then the standard combination of radiation with temozolomide. You must join within 2-3 weeks after completing radiation, but you are encouraged to talk to the participating center closest to you as soon as possible after diagnosis, as it will take some time to evaluate your eligibility. A live tumor sample is NOT required - just the sample that is usually saved after every surgery (block or slides). CDX-110 is an immunotherapeutic molecule that is intended to induce a tumor-specific immune response in EGFRvIII positive brain cancer. Cells producing EGFRvIII have an enhanced capacity for unregulated growth, survival, invasion, and recruitment of new tumor blood vessels. This Phase II/III study is designed to determine whether the addition of CDX-110 vaccination to a standard of care regimen provides significant benefit for patients. THIS trial is not placebo controlled. Every participant gets thevaccine!

		Treatment Type:		Chemotherapy Radiation Immunological, Biological or Targeted Therapy

		Contact:		Patrick Wen MD Dana-Farber Cancer Institute Center for Neuro-Oncology Boston, MA USA Phone: 617-632-6327 Fax: E-mail: Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2010 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By